NCT00562419

CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan

Phase 2, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 Monotherapy and Combination Therapy With Irinotecan in Patients With Recurrent Glioblastoma Multiforme

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 72 (estimated)
• Sponsor: Adnexus, A Bristol-Myers Squibb R&D Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: CT-322 may stop the growth of glioblastoma multiforme by blocking blood flow to the tumor. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving CT-322 together with irinotecan may kill more tumor cells. PURPOSE: This phase 2 trial is studying the side effects, tolerability, and efficacy of CT-322 when given alone and in combination with irinotecan to patients with glioblastoma multiforme.

Conditions

• Brain and Central Nervous System Tumors
• Recurrent Glioblastoma Multiforme

Interventions

Type	Name	Description
DRUG	CT-322	IV solution, weekly
DRUG	irinotecan hydrochloride	IV solution, biweekly

Timeline

• Start date: 2007-10-01
• Primary completion: 2011-06-01
• Completion: 2011-12-01
• First posted: 2007-11-22
• Last updated: 2010-10-27

Locations

10 sites across 1 country: United States